193-OR: Memory Advancement with Intranasal Insulin in Type 2 Diabetes: Randomized Control Trial
NOVAK V, MANTZOROS C, NOVAK P, MCGLINCHEY R, DAI W, LIOUTAS V, BUSS S, FORTIER C, KHAN F, BECERRA L, NGO L. 193-OR: Memory Advancement with Intranasal Insulin in Type 2 Diabetes: Randomized Control Trial. Diabetes 2021, 70 DOI: 10.2337/db21-193-or.Peer-Reviewed Original ResearchIntranasal insulinSpouse/partnerT2DM-related cognitive impairmentType 2 diabetes mellitusPhase 2 trialSignificant adverse eventsRisk of dementiaDual-task walkingNovo NordiskPseudo-continuous arterial spin labelingArterial spin labelingWorld Health OrganizationAdvisory PanelAdverse eventsDiabetes mellitusPrimary outcomeDual taskT2DM participantsKidney diseaseBlind trialControl trialDrug AdministrationType 2Cognitive impairmentT2DM719-P: Caloric Intake, Appetite, and Body Composition Outcomes of Long-Term Intranasal Insulin (INI) Administration: A Substudy of the Memory Advancement by INI in Type 2 Diabetes (MemAID) Study
BECERRA L, KHAN F, NGO L, NOVAK V, MANTZOROS C, GAVRIELI A, UPADHYAY J. 719-P: Caloric Intake, Appetite, and Body Composition Outcomes of Long-Term Intranasal Insulin (INI) Administration: A Substudy of the Memory Advancement by INI in Type 2 Diabetes (MemAID) Study. Diabetes 2021, 70 DOI: 10.2337/db21-719-p.Peer-Reviewed Original ResearchType 2 diabetesSecondary outcomesSpouse/partnerCaloric intakeFood intakeAnthropometric measuresBody compositionIntranasal insulin administrationBody composition outcomesType 2 Diabetes StudyWeeks of treatmentNovo NordiskWorld Health OrganizationAdvisory PanelPrimary outcomeIntervention visitsInsulin resistanceKidney diseaseDiabetes StudyInsulin administrationBody fatBlind trialAnimal studiesComposition outcomesDrug Administration